【导读】*ST苏吴董事长钱群山因涉嫌信息披露违法违规被立案 "披星戴帽"的*ST苏吴又遇新麻烦。 5月14日晚，*ST苏吴发布公告称，收到公司董事长钱群山通知，其于近日收到中国证监会的《立案告知书》，因涉嫌信 息披露违法违规，根据《中华人民共和国证券法》《中华人民共和国行政处罚法》等法律法规，中国证监会决定对其立 案。 公司麻烦缠身 2025年2月，*ST苏吴因信披违规被证监会立案调查；4月23日，*ST苏吴称，公司存在重大违法强制退市风险。次日， *ST苏吴股价开盘后快速跌停，并连续跌停7个交易日。 5月5日晚间，*ST苏吴发布公告，因公司2024年度财务报告被出具"无法表示意见"的审计报告，叠加控股股东浙江复基控 股集团有限公司（以下简称复基控股）的其他关联方企业存在非经营性占用公司资金的情形，公司股票自5月6日起被实 施退市风险警示和其他风险警示，简称变更为"*ST苏吴"。 记者注意到，审计机构对*ST苏吴出具"无法表示意见"的原因主要有三个方面：公司应收账款及票据逾期、子公司骗税案 悬而未决、证监会立案调查。 年报显示，截至2024年年末，*ST苏吴贸易业务应收账款余额为10.62亿元，其中10.27 ...

每经记者｜黄海 每经编辑｜董兴生 "夺章风波"已过去半年有余，庚星股份（现*ST庚星，SH600753 下文均称"庚星股份"）前管理团队部分成员与公司之间再起波澜。因离职 至今没能收到相应补偿，庚星股份多名前高管对前东家提起仲裁或诉讼。 据知情人士透露，截至目前，还有多名庚星股份前高管仍与公司存在劳动合同纠纷。除前董事兼总经理汤永庐外，还包括公司前副总经理 梁明媚、前财务金融中心副总监周雯瑶、前董秘李秀新、前监事陈雪敏等。 双方矛盾实际由来已久。2024年初，庚星股份原控股股东持股被法拍，浙江海歆能源有限责任公司（以下简称"浙江海歆"）拍下部分股 份，成为上市公司第一大股东。自此，浙江海歆与公司原管理团队开始出现摩擦。 到了去年7月底，浙江海歆提议召开临时股东大会，提议罢免庚星股份原董事会的大部分成员。约一个月后，庚星股份又进一步公告称，董 事会同意解聘公司大部分高管。彼时，新老管理团队曾围绕公司公章、证照等展开几轮争夺，最终达成和解。 庚星股份曾在今年1月和4月披露过两份关于重大诉讼及累计诉讼、仲裁情况的公告。两份公告侧面记录了新团队与庚星股份老员工之间的 纠纷进展。 在庚星股份1月8日凌晨的公告中，公司及 ...

Core Viewpoint - The company is facing significant financial challenges due to the non-repayment of funds by its controlling shareholder and related parties, which could lead to severe consequences including stock suspension and delisting if not resolved promptly [1][2]. Group 1: Financial Issues - The controlling shareholder, Dongfang Shishang Investment, and its affiliates have cumulatively repaid 0 yuan of the occupied funds, with a remaining balance of approximately 387 million yuan [1]. - The company has initiated legal action regarding non-operational fund occupation through accounts receivable factoring, but the court did not support the company's claims [1]. - The company is also pursuing legal action against Beijing Tonglong Automobile Sales Co., Ltd. for the non-delivery of an AI intelligent driving training system, with the case yet to be heard [1]. Group 2: Regulatory Risks - According to the Shanghai Stock Exchange regulations, if the company fails to recover the 387 million yuan within six months (by June 19, 2025), its stock will be suspended [2]. - If the company does not complete the required rectification within two months after suspension, it will face a delisting risk warning [2]. - Continued failure to rectify the situation within the subsequent two months could lead to the termination of the company's stock listing [2].

Core Viewpoint - The chairman of *ST Suwu is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, which may impact the company's financial reporting and operations in the future [1][2]. Group 1: Investigation and Regulatory Actions - The CSRC has issued a notice of investigation against chairman Qian Qunshan, which is solely directed at him and is not expected to significantly affect the company's daily operations [1]. - The company has received a non-standard opinion on its 2024 annual report due to issues related to the occupation of funds, with a significant amount of 769 million yuan occupied by related parties [4]. - The company will provide weekly updates on the investigation's progress during the ongoing inquiry [2]. Group 2: Financial Performance - For the year 2024, *ST Suwu reported a revenue of 1.599 billion yuan, representing a year-on-year decrease of 28.64%, and a net profit attributable to shareholders of 70.48 million yuan [4]. - The company has received an audit report from Zhongxing Caiguanghua Accounting Firm that expresses an inability to provide an opinion on the financial statements due to the aforementioned issues [4]. Group 3: Business Operations and Strategy - *ST Suwu operates in the pharmaceutical sector through its wholly-owned subsidiary, Jiangsu Wuzhong Pharmaceutical Group, focusing on drug research, production, and sales, with key products in various therapeutic areas [2]. - The company aims to develop a dual-driven strategy focusing on both industrial development and capital operations, with plans to enhance its pharmaceutical core while nurturing the medical beauty biotechnology sector as a complementary industry [4]. Group 4: Legal and Financial Challenges - The company’s subsidiary, Jiangsu Wuzhong Import and Export Co., faced legal issues related to export tax fraud, with a court hearing scheduled for April 22, 2025 [5]. - Due to overdue loans, some of the company's bank accounts have been frozen, which may further impact its financing capabilities and business operations [5].

Group 1 - The core viewpoint of the articles highlights the trend of well-known listed companies facing delisting from the A-share market due to financial difficulties and inability to adapt to market changes [1][2][4] - Renrenle, a regional supermarket chain leader, received a notice of termination of listing due to a negative net asset of -404 million yuan and an audit report that could not express an opinion, leading to a proposed delisting by the Shenzhen Stock Exchange [1] - Renrenle's revenue has significantly declined from over 10 billion yuan in previous years to 1.43 billion yuan in 2024, marking a nearly 90% decrease from its peak [1][3] Group 2 - Peng Bo Shi, another A-share listed company, also received a notice of proposed termination of listing, having seen its market value shrink from over 60 billion yuan to approximately 1 billion yuan, a reduction of over 98% [2][3] - The decline of these companies reflects broader trends in the market where failure to adapt to economic changes and consumer preferences can lead to severe operational challenges and potential extinction [3][4] - Companies must continuously strengthen their core competitiveness and adapt their business models to meet evolving consumer demands and market conditions to avoid being eliminated from the capital market [4]

Core Insights - JD Group reported Q1 2025 revenue of RMB 301.1 billion, a year-on-year increase of 15.8%, with net profit attributable to ordinary shareholders at RMB 10.89 billion, up 52.73% [1] - Goldman Sachs anticipates continued revenue growth momentum for JD Retail in Q1, with a projected net profit of RMB 10.5 billion [1] - The overall earnings outlook for major stocks remains positive, driven by strong consumer spending trends and growth in AI cloud services [2] Company-Specific Insights Tencent - Tencent's Q1 revenue is expected to show a 15% increase in gaming revenue and an 18% rise in advertising revenue, with adjusted EBITDA projected at RMB 67.8 billion, a 16% year-on-year growth [4] - The company is focusing on AI-driven advertising technology upgrades and the sustainability of gaming revenue growth [5][6] Alibaba - Alibaba's Q1 forecast includes single-digit growth in GMV and a 9% increase in customer management revenue, with adjusted EBITDA expected at RMB 39 billion, a 1% year-on-year increase [7] - Key areas of focus include AI cloud revenue growth and the impact of geopolitical changes on international business [8] Pinduoduo - Pinduoduo's Q1 online marketing revenue is projected at RMB 48.9 billion, a 15% increase, while transaction commission revenue is expected to reach RMB 59.6 billion, up 34% [9] - The company faces challenges due to changes in its business model and competition from new entrants [10] Meituan - Meituan's Q1 core local commerce profit is expected to grow by 26% year-on-year, with a 13% increase in food delivery order volume [11] - The company is under scrutiny regarding its ability to maintain profit targets amid increased competition [12] JD Group - JD's Q1 retail EBITDA is projected at RMB 11.9 billion, a 28% year-on-year increase, with a profit margin of 4.7% [13] - Key considerations include the impact of its new food delivery business on overall profitability and the sustainability of revenue growth in the second half of 2025 [14]

证券代码：000004 证券简称：*ST 国华 公告编号：2025-032 深圳国华网安科技股份有限公司 针对上述情况，公司进行了必要核实，对影响公司价格异常波动的事项说明 如下： 大影响的未公开重大信息。 大事项，或处于筹划阶段的重大事项。 三、不存在应披露而未披露的重大信息的声明 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 一、股票交易异常波动的情况 深圳国华网安科技股份有限公司（以下简称"公司"）股票（证券简称：*ST 国华，证券代码：000004）于 2025 年 5 月 9 日、5 月 12 日、5 月 13 日连续三个 交易日内日收盘价格涨幅偏离值累计超过 12%，根据《深圳证券交易所交易规则》 的有关规定，属于股票交易异常波动情况。 二、公司关注、核实的相关情况 公司董事会确认，公司目前没有任何根据深交所《股票上市规则》等有关规 定应予以披露而未披露的事项或与该事项有关的筹划、商谈、意向、协议等；董 事会也未获悉公司有根据深交所《股票上市规则》等有关规定应予以披露而未披 露的、对公司股票及其衍生品种交易价格产生较大影响的信息；公司前期披露的 ...

Core Viewpoint - The stock of Jinzhou Port Co., Ltd. has experienced abnormal trading fluctuations, with a cumulative closing price drop exceeding 12% over three consecutive trading days, prompting a risk warning from the Shanghai Stock Exchange [1][2]. Group 1: Stock Trading Abnormalities - The company's B-share stock closed with a cumulative price drop exceeding 12% on May 9, May 12, and May 13, 2025, which is classified as an abnormal trading situation according to the Shanghai Stock Exchange rules [1]. - The company conducted a self-examination and confirmed that there are no undisclosed significant matters or important information aside from what has already been disclosed [1][2]. Group 2: Business Operations - The company's core business of port comprehensive transportation services remains stable, with no significant changes in production operations or market environment as of the announcement date [1][2]. Group 3: Major Events and Information - The company has no controlling shareholder or actual controller, and there are no undisclosed major events such as asset restructuring, share issuance, or significant business cooperation [2]. - There have been no media reports or market rumors that could significantly impact the company's stock price [2]. Group 4: Risk Warnings - The company's stock has been trading below RMB 1 for six consecutive trading days, which may lead to potential delisting risks if the situation continues [3]. - The company faces risks of mandatory delisting due to false disclosures in its annual reports from 2020 to 2023, as identified by the China Securities Regulatory Commission [3][4]. - The company has received a negative opinion on its internal control audit for the 2024 financial report, which could lead to further delisting risks if similar issues persist in future reports [5].

证券代码： 300125 证券简称：*ST 聆达 4、公司有退市风险吗 公司 2024 年度经审计的扣除非经常性损益后的净利润为 -85,579 万元且扣除后营业收入为 5,785 万元，期末净资产为 -53,841 万元。根据《上市规则》第 10.3.1 条第一款第（一） （二）项规定：上市公司出现"最近一个会计年度经审计的利润 总额、净利润、扣除非经常性损益后的净利润三者孰低为负值， 且扣除后的营业收入低于 1 亿元的情形。"；"最近一个会计年 度经审计的期末净资产为负值"，公司股票交易于 2025 年 4 月 25 日起被实施退市风险警示。如公司 2025 年度出现《上市规则》 第 10.3.11 规定的第（一）项至第（十）项关于终止公司股票上 市交易的相关情形，深圳证券交易所将终止公司股票上市交易。 5、预计会在什么时候得到法院批准重整？ 投资者您好，公司严格按照深圳证券交易所信息披露要求履 行信披义务，公司预重整相关进展情况请关注后续公告和全国企 业破产重整案件信息网，感谢您的关注。 聆达集团股份有限公司投资者关系活动记录表 | 投资者关系活动 | □特定对象调研 □ 分析师会议 | | --- | ...

Group 1: Company Performance and Strategies - The company plans to increase R&D investment to enhance product market share and revenue [1][3][6] - Expansion of entrusted business to improve revenue generation capabilities [1][3][6] - Optimization of operational processes to reduce operating costs and enhance profitability [1][3][6] - Streamlining organizational structure to improve operational efficiency and control labor costs [1][3][6] - Expansion of export activities to create new profit growth points [1][3][6] Group 2: Risk Management and Future Plans - The company is actively taking measures to mitigate delisting risks, including adapting to new healthcare policies and participating in procurement [6][9] - Focus on maintaining existing customer orders in the peptide business while expanding customer channels [7][9] - Commitment to advancing the approval of products under review and engaging in international business development activities [7][9] - Emphasis on cost control measures to enhance efficiency and reduce waste [7][9] Group 3: Acquisition and Restructuring - The company currently has no acquisition plans, and all relevant information will be disclosed through designated media [2][4][8] - Suggestions from investors regarding restructuring and acquisitions have been acknowledged, but no concrete plans are in place [2][3][4][8]